CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

Prior treatment

• Stand- alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and/or valve surgery
• Prior cardiac surgery including prior cardiac surgical ablation
• Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation)
• Prior history of stroke within 6 months
• Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment
• A known drug and/or alcohol addiction
• Subjects who have been treated with thoracic radiation
• Subjects in current chemotherapy
• Subjects on long-term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases)
• Solid organ or hematologic transplant, or currently being evaluated for an organ transplant
• Use of any other investigational drug, therapy, or device within 30 days before enrollment or concurrent participation in another research study

Other illness

• Subject has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter-defibrillator (ICD), or Cardiac Resynchronization Therapy (CRT) or left atrial appendage (LAA) device
• Subject has a prosthetic heart valve
• Wolff-Parkinson-White syndrome or other Supra-Ventricular Arrhythmia, Atrioventricular (AV) nodal reentry
• Documented history of persistent or long standing persistent atrial fibrillation longer than 10 years
• Subjects requiring surgery other than CABG and/or cardiac valve surgery and/or atrial septal defect repair/PFO and ascending aorta
• Subjects that are on an AAD for ventricular arrhythmia.
• Class III or IV New York Heart Association (NYHA) heart failure symptoms
• Need for emergent cardiac surgery (per sit-to-stand (STS) test definition)
• Current diagnosis of active systemic infection
• Severe peripheral arterial occlusive disease defined as claudication with minimal exertion
• Renal failure requiring dialysis or hepatic failure (significant liver dysfunction with markedly significant elevation of liver enzymes, such as cirrhosis with decompensation, portal hypertension, or a history of hepatic failure)
• Mental impairment or other conditions that may not allow the subject to understand the nature, significance, and scope of the study
• Subject has a contraindication to anticoagulation (e.g., a bleeding or clotting disorder such as Idiopathic Thrombocytopenic Purpura (ITP))
• Any diagnosed connective tissue disorder
• Severe Chronic Obstructive Pulmonary Disease (COPD) per sit-to-stand (STS) test definition

Other

• Subject has history or known to have LAA clot
• Left Atrial diameter ≥ 6cm
• STS Predicted Risk of Mortality (STS PROM) of 10 or higher
• Known carotid artery stenosis greater than 80%
• Pregnancy or desire to get pregnant within 12 months of the study treatment
• Preoperative need for an intra-aortic balloon pump or intravenous inotropes
• Subjects with known hypertrophic obstructive cardiomyopathy
• Subjects with known cold agglutinin
• Body mass index \> 45 kg/m2

• Subject must be between 18 and 85 years of age
• Subject is willing and capable of providing Informed Consent to undergo study procedures which include the potential for surgical AF ablation, and completion of follow-up visits as specified in the clinical study protocol
• Subject has history of documented paroxysmal atrial fibrillation (AF that is intermittent and terminates within ≤ 7 days of onset) or persistent/longstanding persistent atrial fibrillation (AF that is continuous and sustains for \> 7 days and requires intervention) within one year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), Holter monitor or telemetry strip from the study hospital or an outside physician
• Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery via sternotomy for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, Atrial Septal Defect (ASD)/Patent Foramen Ovale (PFO) or Coronary artery bypass procedures
• Left ventricular ejection fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)
• Subject has a life expectancy of at least 5 years
• Subject currently lives within a reasonable commuting distance of the investigational site and plans to remain geographically stable through 12 month follow up